注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
TFF Pharmaceuticals Inc是一家临床阶段的生物制药公司,专注于基于其专利薄膜冷冻(TFF)技术平台开发和商业化创新药物产品。TFF平台旨在提高水溶性差的药物的溶解度和吸收性,尤其适用于生成具有针对吸入递送特性的干粉颗粒,特别是针对深肺这一呼吸医学领域极为感兴趣的领域。TFF Pharmaceuticals有两种主要候选药物:吸入伏立康唑粉(TFF Vori)和吸入他克莫司粉(TFF Tac-Lac)。该公司正在与Augmenta BioWorks合作开发吸入性SARS-CoV2单克隆抗体,并在合作协议中参与开发氯硝柳胺的干粉制剂。它还通过局部、眼部和鼻部应用积极参与多种药物和疫苗的干粉制剂的分析和测试。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Anthony J. Hickey | - | 2022 | Chairman of the Scientific Advisory Board and Senior Research & Development Advisor |
David N. Cornfield | - | 2021 | Member of Scientific Advisory Board |
Stephen Charles Rocamboli | 51 | 2018 | Independent Director |
Ted M. Ross | - | 2021 | Member of Scientific Advisory Board |
Drew Weissman | - | 2021 | Member of Scientific Advisory Board |
Mike Saag | - | 2021 | Member of Scientific Advisory Board |
Robert S. Mills | 70 | 2018 | Independent Director |
Harlan F. Weisman | 71 | 2018 | President, CEO & Director |
Jay Peters | - | 2021 | Member of Scientific Advisory Board |
David W. Denning | - | 2021 | Member of Scientific Advisory Board |
Brandi L. Roberts | 49 | 2022 | Independent Director |
Michael A. Patane | 59 | 2023 | Independent Director |
Thomas B. King | 69 | 2023 | Independent Director |
Catherine C. Lee | 50 | 2023 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核